MaaT Pharma SA (EPA:MAAT)

MaaT Pharma Statistics

Total Valuation

MaaT Pharma has a market cap or net worth of EUR 60.88 million. The enterprise value is 60.24 million.

Market Cap	60.88M
Enterprise Value	60.24M

Important Dates

The next estimated earnings date is Monday, March 30, 2026.

Earnings Date	Mar 30, 2026
Ex-Dividend Date	n/a

Share Statistics

MaaT Pharma has 16.11 million shares outstanding. The number of shares has increased by 22.07% in one year.

Current Share Class	16.11M
Shares Outstanding	16.11M
Shares Change (YoY)	+22.07%
Shares Change (QoQ)	+8.46%
Owned by Insiders (%)	1.66%
Owned by Institutions (%)	44.10%
Float	1.80M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	15.52
PB Ratio	7.34
P/TBV Ratio	11.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.94
EV / Sales	15.36
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.37

Financial Position

The company has a current ratio of 2.22, with a Debt / Equity ratio of 1.74.

Current Ratio	2.22
Quick Ratio	2.15
Debt / Equity	1.74
Debt / EBITDA	n/a
Debt / FCF	-0.57
Interest Coverage	-27.56

Financial Efficiency

Return on equity (ROE) is -183.64% and return on invested capital (ROIC) is -58.07%.

Return on Equity (ROE)	-183.64%
Return on Assets (ROA)	-38.10%
Return on Invested Capital (ROIC)	-58.07%
Return on Capital Employed (ROCE)	-92.65%
Revenue Per Employee	60,338
Profits Per Employee	-478,969
Employee Count	67
Asset Turnover	0.08
Inventory Turnover	13.93

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -51.54% in the last 52 weeks. The beta is -0.07, so MaaT Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.07
52-Week Price Change	-51.54%
50-Day Moving Average	4.18
200-Day Moving Average	5.29
Relative Strength Index (RSI)	35.79
Average Volume (20 Days)	46,048

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, MaaT Pharma had revenue of EUR 3.92 million and -31.13 million in losses. Loss per share was -2.15.

Revenue	3.92M
Gross Profit	2.06M
Operating Income	-30.42M
Pretax Income	-31.13M
Net Income	-31.13M
EBITDA	-30.21M
EBIT	-30.42M
Loss Per Share	-2.15

Balance Sheet

The company has 15.04 million in cash and 14.41 million in debt, giving a net cash position of 633,000 or 0.04 per share.

Cash & Cash Equivalents	15.04M
Total Debt	14.41M
Net Cash	633,000
Net Cash Per Share	0.04
Equity (Book Value)	8.30M
Book Value Per Share	0.55
Working Capital	19.53M

Cash Flow

In the last 12 months, operating cash flow was -24.67 million and capital expenditures -783,000, giving a free cash flow of -25.45 million.

Operating Cash Flow	-24.67M
Capital Expenditures	-783,000
Free Cash Flow	-25.45M
FCF Per Share	-1.58

Margins

Gross Margin	52.40%
Operating Margin	-775.65%
Pretax Margin	-793.80%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

MaaT Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.07%
Shareholder Yield	-22.07%
Earnings Yield	-51.14%
FCF Yield	-41.81%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

MaaT Pharma has an Altman Z-Score of -0.42 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.42
Piotroski F-Score	4